Charles Darwin University

CDU eSpace
Institutional Repository

 
CDU Staff and Student only
 

Rosiglitazone: rosy news for a thiazolidinedione

Doggrell, SA (2007). Rosiglitazone: rosy news for a thiazolidinedione. Expert Opinion on Pharmacotherapy,8(2):265-268.

Document type: Journal Article
Citation counts:
Google Scholar Search Google Scholar

Title Rosiglitazone: rosy news for a thiazolidinedione
Author Doggrell, SA
Journal Name Expert Opinion on Pharmacotherapy
Publication Date 2007
Volume Number 8
Issue Number 2
Start Page 265
End Page 268
Publisher Informa Healthcare
HERDC Category C1 - Journal Article (DEST)
Abstract Thiazolidinediones are known to increase insulin sensitivity and to be useful in the treatment of Type 2 diabetes. Recently, other important benefits of the thiazolidinediones have emerged. one of the thiazolidinediones (rosiglitazone) has been shown to prevent the progression from a pre-diabetic state to diabetes. In subjects with impaired fasting glucose or impaired glucose tolerance, the diabetic rate over 3 years was 25.0% in the placebo group and 11.6% in the rosiglitazone group. Another recent clinical trial with rosiglitazone has shown that it reduced microalbuminuria and blood pressure independently of glycaemia in subjects with Type 2 diabetes and microalbuminuria. After 32 weeks, there was a 22.7% reduction in the urine albumin:creatinine ratio with rosiglitazone.
Keywords impaired fasting glucose
impaired glucose tolerance
microalbuminuria
rosiglitazone
thiazolidinediones
type 2 diabetes
RANDOMIZED CONTROLLED-TRIAL
BETA-CELL FUNCTION
HISPANIC WOMEN
PREVENTION
PIOGLITAZONE
RISK
DOI http://dx.doi.org/10.1517/14665666.8.2.265   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)
 
Versions
Version Filter Type
Access Statistics: 35 Abstract Views  -  Detailed Statistics
Created: Mon, 08 Sep 2008, 16:16:22 CST